



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

| | | |
|---|-----------|---|
| (51) International Patent Classification ⁵ : C07K 15/12, A61K 37/02 C12P 21/08, G01N 33/577, 33/92 C12N 15/12 | A1 | (11) International Publication Number: WO 90/05748 (43) International Publication Date: 31 May 1990 (31.05.90) |
| (21) International Application Number: PCT/US89/05116 (22) International Filing Date: 14 November 1989 (14.11.89) (30) Priority data: <div style="display: flex; justify-content: space-between;"> <div>272,002</div> <div>15 November 1988 (15.11.88)</div> <div>US</div> </div> <div style="display: flex; justify-content: space-between;"> <div>391,486</div> <div>9 August 1989 (09.08.89)</div> <div>US</div> </div> (71) Applicant (for all designated States except US): MASSACHUSETTS INSTITUTE OF TECHNOLOGY [US/US]; 77 Massachusetts Avenue, Cambridge, MA 02139 (US). (72) Inventors; and (75) Inventors/Applicants (for US only) : KODAMA, Tatsuhiko [JP/US]; 6 Cotter Road, Waban, MA 02168 (US). KRIEGER, Monty [US/US]; 139 Woodbine Circle, Needham, MA 02194 (US). (74) Agents: ENGELLENER, Thomas, J. et al.; Lahive & Cockfield, 60 State Street, Boston, MA 02109 (US). | | (81) Designated States: AT (European patent), BE (European patent), CH (European patent), DE (European patent), FR (European patent), GB (European patent), IT (European patent), JP, LU (European patent), NL (European patent), SE (European patent), US. Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i> |
| (54) Title: SCAVENGER RECEPTOR PROTEIN AND ANTIBODY THERETO (57) Abstract <p>A substantially pure receptor protein capable of binding acetylated low density lipoprotein and oxidized low density lipoprotein is disclosed herein. This protein is characterized by having a molecular weight of about 220,000 daltons, and an affinity for oxidized low density lipoprotein and acetylated low density lipoprotein. Further, it is an integral membrane protein which includes a collagen domain. Proteins having an affinity for the receptor protein as well as DNA sequences encoding at least a portion of the receptor protein are also disclosed herein. In addition, devices for purification purposes and methods for detecting atherosclerotic plaques are described, both of which utilize the receptor protein or binding proteins thereto.</p> | | |

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

| | | | | | |
|----|------------------------------|----|--|----|--------------------------|
| AT | Austria | ES | Spain | MG | Madagascar |
| AU | Australia | FI | Finland | ML | Mali |
| BB | Barbados | FR | France | MR | Mauritania |
| BE | Belgium | GA | Gabon | MW | Malawi |
| BF | Burkina Faso | GB | United Kingdom | NL | Netherlands |
| BG | Bulgaria | HU | Hungary | NO | Norway |
| BJ | Benin | IT | Italy | RO | Romania |
| BR | Brazil | JP | Japan | SD | Sudan |
| CA | Canada | KP | Democratic People's Republic of Korea | SE | Sweden |
| CF | Central African Republic | KR | Republic of Korea | SN | Senegal |
| CG | Congo | LI | Liechtenstein | SU | Soviet Union |
| CH | Switzerland | LK | Sri Lanka | TD | Chad |
| CM | Cameroon | LU | Luxembourg | TG | Togo |
| DE | Germany, Federal Republic of | MC | Monaco | US | United States of America |
| DK | Denmark | | | | |

-1-

SCAVENGER RECEPTOR PROTEIN AND ANTIBODY THERETOBackground of the Invention

The U.S. Government has rights in this invention pursuant to NIH Grant No. 5R01HL33516-03.

The technical field of this invention is devices and methods for the diagnosis and treatment of atherosclerosis, and, in particular, devices and methods utilizing receptor proteins associated with atherosclerotic plaques and/or monoclonal antibodies thereto.

Atherosclerosis is a disease which causes the thickening and hardening of the arteries, particularly of the larger arteries. It is characterized by raised fibrous plaques or lesions within the arterial lumen which form as the result of the deposition of plasma cholesterol and low density lipoproteins (LDL).

Key cellular components of the atherosclerotic plaque are foam cells which are derived from phagocytic macrophages of monocytic origin. Macrophages and foam cells have surface receptor proteins which have an affinity for

circulating LDL, and which are directly responsible for the receptor-mediated ingestion, or endocytosis, of such material.

These cells also have a receptor-mediated ability to bind and endocytose chemically modified LDL, such as acetylated-LDL (Ac-LDL), acetoacetylated LDL (AcAc-LDL), and oxidized LDL (Ox-LDL), as well as a limited range of other negatively charged macromolecules. This receptor activity has been found to be inducible in monocytes and macrophages under certain conditions, and has been implicated in the formation of foam cells, and hence of atherosclerotic plaques (Goldstein et al. vol. 76, Proc. Natl. Acad. Sci. (USA), pp. 333-337 (1980); Brown et al. vol. 52, Ann. Rev. Biochem., pp. 222-226 (1983)).

The injuries or deformities of the arterial lumen caused by the plaque and associated deposits result in occluded blood flow, and ultimately in a number of related conditions if left untreated, such as, angina, cerebral ischemia, renal hypertension, ischemic heart disease, stroke, and diseases of other organs. Coronary atherosclerosis is still the leading cause of death in the United States and in other industrially advanced countries.

Unfortunately, there are no existing diagnostic methods which can reliably detect these diseases. The early stages of atherosclerosis and related vascular diseases often have no clinically manifestations. Because lifestyle changes, drug therapy, and other means exist for delaying or

-3-

reducing vascular occlusion or the stresses on various body organs which result from atherosclerotic lesions, the early detection of atheromatous plaques would be of considerable value in permitting preventive intervention at a time when it can be most effective.

Arteriography is the conventional approach to diagnosing advanced vascular disease. This procedure involves the imaging of obstructions in the arteries via catheterization and the injection into the bloodstream of radioopaque substances. However, significant morbidity can result from this procedure due to the increased chances of infection, perforation of the artery, arrhythmia, stroke, and infarction. Because of the risks involved, arteriograms typically are reserved for individuals with advanced or acute atherosclerotic disease, ruling out this method for preventative therapy.

A variety of less invasive techniques for the diagnosis of vascular injury and disease have been used. These techniques include plethysmography, thermography, and ultrasonic scanning. (For a review of these procedures, see Lees and Myers, Vol. 27, Adv. Int. Med., pp. 475-509 (1982)). However, none of these imaging techniques have achieved clinical acceptance.

Other non-invasive approaches to the diagnosis of vascular injury include the administration of injectible, detectible agents to the vascular system of a patient which are capable of recognizing, binding to, and/or being internalized

by, atherosclerotic lesions. Such procedures include the administration of hematoporphyrin (as described in U.S. 4,577,636, issued to Spears), monoclonal antibodies (EPO 85402359.5 issued to Takano), or magnetic particles capable of being inductively heated (as described in U.S. 4,359,453 issued to Gordon).

Because LDL is known to be deposited in atherosclerotic plaques, methods employing labelled LDL have been utilized to target plaques (see, for example, U.S. Patent Nos. 4,647,445 and 4,660,563 issued to Lees). A disadvantage to these methods is that several days are typically required to isolate LDL from the patient's blood and to label them. Often, such a delay in diagnosis and subsequent treatment is detrimental for critically ill patients. Furthermore, an additional risk of viral infection can arise if donor blood is employed as an LDL source.

Consequently, there exists a need for better non-invasive techniques and reagents capable of detecting, mapping, and treating early, non-stenosing, non-flow-disturbing atherosclerotic arterial lesions.

Accordingly, it is an object of the present invention to provide methods for the early detection of atherosclerosis and other related vascular diseases. It is also an object of the present invention to identify a component of the arterial plaque which is key in detecting and mapping an abnormal region of the vascular system, or a region

predisposed to atherosclerosis. Yet another object of the invention is to provide a detection method which is non-invasive. A further object of the present invention is to provide devices and methods for locating and quantitating the extent of arterial plaque build up. Another object is to provide a method for treating atherosclerosis.

Summary of the Invention

Receptor proteins, antibodies thereto, and methods and devices utilizing such receptor proteins and antibodies are disclosed herein for the detection and treatment of atherosclerosis. A new receptor protein has been discovered which is capable of binding chemically modified forms of LDL such as acetyl-LDL (Ac-LDL). This receptor protein is found on the surface of macrophages and plaque-forming components. The term "plaque-forming component" is used herein to encompass cells associated with the plaque and/or involved in its genesis such as foam cells, macrophages, and monocytes.

The new receptor protein, referred to hereinafter as the "scavenger receptor protein", or the "receptor protein" has an apparent molecular weight on SDS-polyacrylamide gels of about 220,000 daltons (220 kD), and a binding affinity for Ac-LDL of about 0.5 micrograms per milliliter. It is further characterized as being a trimer of subunits, each of which having an apparent molecular weight on SDS-polyacrylamide gels of about 77 kD, and as including an asparagine (Asn)-linked carbohydrate chain.

In addition, it appears that this novel receptor protein includes not only a region or domain which spans the membrane followed by an alpha-helical triple coiled coil domain, but also an extracellular collagen domain. The term "collagen domain" is used herein to encompass a region of a polypeptide which is substantially analogous to that of collagen or an

analog or portion thereof. This collagen domain is found in each of the three subunits.

The present invention includes a substantially pure scavenger receptor protein and an active fragment, analog, and derivative thereof. One embodiment of the invention includes a polypeptide having an amino acid sequence sufficiently duplicative of the amino acid sequence of a subunit of the scavenger receptor protein such that said polypeptide, when trimerized with two of said polypeptides or with two subunits of the scavenger receptor protein, binds chemically modified forms of LDL. The invention also includes DNA sequences encoding active fragments, derivatives, and subunits thereof.

Further, invention includes a binding reagent with an affinity for the scavenger receptor protein or specific portion thereof. In a preferred embodiment, a monoclonal antibody is disclosed as a binding agent with a specific affinity for the scavenger receptor protein. Such a device could be used to bind various molecules for which the receptor proteins, or fragments or analogs thereof, have affinity.

In one aspect of the invention, a device for assay or purification purposes is disclosed which includes a plurality of scavenger receptor proteins, or fragments or analogs thereof, linked to a support. The invention also includes a device for assay or purification which includes a plurality of

binding reagents with an affinity for the scavenger receptor protein, linked to a support.

In other aspects of the invention, methods utilizing the diagnostic properties of the scavenger receptor protein and the binding reagent thereto are also disclosed. For example, a method of detecting an atherosclerotic plaque is described. In this method, the binding reagent is coupled to a labelling means to form a conjugate. The conjugate is then administered to the vascular system of a subject where it is allowed to bind to the scavenger receptor protein associated with a plaque and/or a plaque-forming component. The presence and location of the labelling means in the vascular system of the subject is then determined, as they are indicative of the presence of an atherosclerotic plaque.

The present invention has therapeutic utility as well. For example, one embodiment includes a method of treating atherosclerosis by the selective delivery of a therapeutic agent to a plaque. In this application, a therapeutic agent is coupled to a binding agent having a specific affinity for the scavenger receptor protein, thereby forming a conjugate therapeutic agent. The conjugate is then administered to the vascular system of the subject where it binds to the receptor protein and delivers the therapeutic agent to the plaque or plaque-forming component.

In further aspects of the invention, methods utilizing antagonists of the scavenger receptor

protein are disclosed for treatment of vascular disease.

The invention will next be described in connection with certain illustrated embodiments. However, it should be clear that various modifications, additions, and subtractions can be made without departing from the spirit or scope of the invention.

Description of the Drawings

The foregoing and other objects of this invention, the various features thereof, as well as the invention itself may be more fully understood from the following description when read together with the accompanying drawings in which:

FIG. 1 is a photographic representation of a non-reducing SDS gel of the partially purified scavenger receptor protein which has been silver stained (A); ligand blotted (B); and immunoblotted (C);

FIG. 2 is a schematic representation of the scavenger receptor protein and its domains;

FIGS. 3A-C are a schematic representation of a first representative nucleic acid sequence and corresponding amino acid sequence of a portion of the protein illustrated in FIG. 2;

FIGS. 4A-D are a schematic representation of a composite nucleic acid sequence and the corresponding amino acid sequence of another overlapping portion of the protein;

FIG. 5 is a photographic representation of the scavenger receptor protein which has been subjected to immunoprecipitation, non-reducing SDS-PAGE and then to autoradiography (A) or ligand blotting (B), or to immunoaffinity purification followed by non-reducing SDS-PAGE and silver staining (C);

-11-

FIG. 6 is a photographic representation of immunoprecipitated 77 kD subunit of the receptor protein which has been digested with sialidase (B) or endoglycosidase F (C) prior to reducing SDS-PAGE;

FIG. 7 is a photographic representation of the immunohistochemical localization of the scavenger receptor protein in bovine liver incubated with (A) control antibody, or (B, C) IgG-D1;

FIG. 8 is a photographic representation of (A) a fluorescence photograph demonstrating the ability of macrophages to take up fluorescent labelled acetyl-LDL in the absence (1) or presence (2) of excess unlabelled acetyl-LDL; and (B) the susceptibility of the scavenger receptor protein to trypsin digestion;

FIG. 9 is a photographic representation of a ligand blot demonstrating the coinduction of the scavenger receptor protein and cellular scavenger receptor-mediated endocytosis in human monocyte (PMA-)/macrophage (PMA+) cell lines;

FIG. 10 is a graphic representation of the binding affinity (A) and specificity (B) of acetyl-LDL binding to the affinity purified receptor protein;

FIG. 11 is a graphic representation of the ability of different concentrations of a number of competitors to inhibit Ac-LDL receptor activity;

-12-

FIG. 12 is a graphic representation of the ability of one concentration of different competitors to inhibit Ac-LDL receptor activity;

FIG. 13 is a photographic representation of an autoradiogram of a Northern blot using RNA isolated from various cell and tissue types and a DNA probe encoding the collagen domain; and

FIGS. 14A-D are a schematic representation of a representative nucleic acid sequence and corresponding amino acid sequence of a subunit of the human scavenger receptor protein.

Detailed Description

The scavenger receptor protein is differentially expressed in various tissues. It can be isolated from various organs and, in particular, from mammalian liver and lung specimens by established purification methods. These procedures include, for example, differential centrifugation, detergent extraction of isolated membrane fractions, ion exchange or exclusion chromatography, and gel chromatography.

Alternatively, purification methods employing an antibody which has a specific affinity for the receptor protein may be employed. For example, the receptor protein may be purified by affinity chromatographic methods in which the antibody is bound to an immobilized matrix or support material in a column; the receptor protein may also be immunoprecipitated from a heterogeneous solution using an anti-receptor protein antibody. Using this methodology, the receptor protein may also be isolated from mammalian foam cells and plaque-forming components such as macrophages .

Using these isolation methods, the scavenger receptor protein has been purified to at least near homogeneity. The protein has an apparent molecular weight on SDS-polyacrylamide gels of about 220 kD (FIG. 1A), and a binding affinity for Ac-LDL. It consists of three seemingly identical subunits, each of which has an apparent molecular weight of about 77 kD (FIGs. 1 and 2), and each apparently having a number of different domains (i.e., Cys-rich domain,

-14-

collagen domain, asparagine-linked sugar domain, transmembrane domain, and cytoplasmic domain) which are depicted in FIG. 2.

As detailed below, a major portion of the amino acid sequence of the protein has been derived from the nucleic acid sequence of a gene encoding the protein. However, because more than one nucleotide triplet (codon) can encode a single amino acid, a number of different nucleotide sequences can encode a single protein. Hence, the peptide fragment disclosed herein may be encoded by nucleic acid sequences which are functionally equivalent to the one shown above, and which may also be prepared by known synthetic procedures. Accordingly, the invention includes such functionally equivalent nucleotide sequences. In addition, one skilled in the art, knowing the amino acid sequence of the receptor protein, could synthetically or biosynthetically prepare a functionally equivalent analog of the receptor protein of the invention having substantially the same biological activity. In particular, fragments of the protein, especially portions of the extracellular domain, can be obtained for the disclosures herein without undue experimentation.

Thus, the scope of the invention includes the amino acid sequences and corresponding nucleic acid sequences depicted herein, as well as all functionally equivalent amino acid sequences (and corresponding nucleic acid sequences) for molecules with substantially the same scavenger receptor protein biological activities. For example, one

-15-

embodiment of the invention includes a polypeptide having an amino acid sequence sufficiently duplicative of the amino acid sequence of a subunit of the scavenger receptor protein such that the polypeptide, when trimerized with two other like polypeptides or with two subunits of the scavenger receptor protein, bind chemically modified forms of LDL..

Furthermore, those skilled in the art of recombinant DNA technology can use a nucleic acid sequence encoding the receptor protein or a fragment thereof to produce a protein, fragment thereof, or an analog thereof in an appropriate microbial or mammalian host cell. For example, the sequence may be inserted into an expression system such as a vector which is suitable for transforming or transfecting a eucaryotic (yeast or mammalian) or prokaryotic (bacterial) host cell. These standard procedures have been followed to produce well-known proteins such as insulin, interferons, human growth hormone, and the like. Similar procedures, or obvious modifications thereof, can also be employed to prepare the scavenger receptor protein, and fragments or analogs thereof in accord with the subject invention.

Using such recombinant DNA methodologies, several clones were prepared which encode at least part of the scavenger receptor protein. Clone 3 encodes at least the membrane spanning (TM) domain and the collagen (Col) domain, as well as an asparagine (Asn)-linked sugar domain (N-linked sugar) including a number of potential sugar linkage sites.

-16-

The nucleic acid sequences and corresponding amino acid sequence of clone 3 is shown in FIGs. 3A-C wherein the first underlined amino acid sequence is that of the membrane spanning domain, the second underlined sequence is that of the collagen domain, and overlined residues 82-84, 101-103, 142-145, 183-186, 220-222, 248-250, 266-268 are the potential sugar linkage sites within the Asn-linked sugar domain.

Clones 7, 12, and 13 include some or all of these domains as well as at least a portion of a cysteine rich domain. A composite nucleic acid sequence and corresponding amino acid sequence of these clones is shown in FIGs. 4A-D.

FIGs. 14A and 14B show a representative nucleic acid sequence and corresponding amino acid sequence of at least part of the human scavenger receptor protein determined using similar DNA methodologies.

TABLE 1 provides the abbreviations for the amino acids shown in FIGs. 3A-C, 4A-D, and 14A-D.

-17-

TABLE 1

| <u>amino acid</u> | <u>abbreviations</u> | <u>amino acid</u> | <u>abbreviations</u> |
|-------------------|----------------------|-------------------|----------------------|
| Alanine | Ala A | Glycine | Gly G |
| Valine | Val V | Serine | Ser S |
| Leucine | Leu L | Threonine | Thr T |
| Isoleucine | Ile I | Cysteine | Cys C |
| Proline | Pro P | Tyrosine | Tyr Y |
| Phenylalanine | Phe F | Asparagine | Asn N |
| Tryptophan | Trp W | Glutamine | Gln Q |
| Methionine | Met M | Aspartic Acid | Asp D |
| Lysine | Lys K | Glutamic Acid | Glu E |
| Argenine | Arg R | Histidine | His H |

TABLE 2 illustrates the location of the various domains within the amino acid sequence of the scavenger receptor protein.

TABLE 2

| <u>amino acid #</u> | <u>Domain</u> | <u>Estimated Mass*</u> |
|---------------------|------------------|------------------------|
| 1 - 50 | Cytoplasmic | 5,740 |
| 51 - 76 | Transmembrane | 2,766 |
| 77 - 271 | Asn-linked Sugar | 22,480 |
| 272 - 343 | Collagen | 6,795 |
| 341 - 453 | Cys-Rich | <u>12,275</u> |
| | | 50,056 total |

*based on the molecular weight of the individual amino acids

Each subunit has at least one asparagine (Asn)-linked carbohydrate chain determined by treatment with various deglycosylation enzymes (FIG. 6). The assignment of the Asn-linked sugar domain is based on the presence of potential Asn-linked sugar attachment sites from the cDNA sequence shown in FIGS. 3A-C, and the finding that several of these show no detectable Asn in the protein sequence, suggesting that the Asn groups are indeed glycosylated. By analysis of its amino acid sequence, this domain appears to have an alpha-helical triple coiled coil structure.

The assignment of residues 341-453 as a Cys-rich domain is based on the fact that it contains multiple Cys amino acids. In addition, because this domain is the most distal external domain, and because several other known cell surface receptors have Cys-rich ligand binding domains, this domain may also serve as a ligand binding site. However, since the collagen domain is positively charged and since the ligands are often negatively charged, the collagen domain alternatively or additionally may participate in ligand binding. The same may be true for a portion or all of the alpha helical triple coiled coil in the Asn-linked sugar domain.

The membrane spanning domain of the scavenger receptor protein includes an amino acid sequence such as:

Thr-Ala-Leu-Ile-Thr-Leu-Thy-Leu-Ile-Val-Phe-
Val-Val-Leu-Val-Pro-Ile-Ile-Gly-Ile-Val-Ala-
Ala-Gln-Leu-Leu.

The collagen domain includes an amino acid sequence such as:

Gly-Pro-Pro-Gly-Pro-Pro-Gly-Glu-Lys-Gly-Asp-Arg-Gly-Pro-Pro-Gly-Gln-Asn-Gly-Ile-Pro-Gly-Phe-Pro-Gly-Leu-Ile-Gly-Thr-Pro-Gly-Leu-Lys-Gly-Asp-Arg-Gly-Ile-Ser-Gly-Leu-Pro-Gly-Val-Arg-Gly-Phe-Pro-Gly-Pro-Met-Gly-Lys-Thr-Gly-Lys-Pro-Gly-Leu-Asn-Gly-Gln-Lys-Gly-Glu-Lys-Gly-Ser-Gly.

The finding of a collagen-like domain (collagen domain) is consistent with the fact that the scavenger receptor is a trimer. Collagen domains are known to form triple helical trimers in those molecules which have such domains (e.g., collagens, Clq, acetylcholine esterase, serum mannose binding proteins, and lung surfactant protein). This is also true of the alpha helical triple coiled coil in the Asn-linked sugar domain.

The proposed orientation of the receptor shown in FIG. 2 (N-terminus inside, C-terminus outside) is based on the following: 1) there is only one membrane spanning domain; 2) there is no N-terminal signal sequence (presumably, the transmembrane domain is also the signal for membrane insertion); 3) the Asn-linked sugar domain and the collagen domain are expected to be extracellular since the domains have never been found to be cytoplasmic on other proteins); and 4) the charged amino acids surrounding the transmembrane domain have a polarity consistent with the protein being N-terminus in, C-terminus out.

-20-

The scavenger receptor protein, having several extracellular domains, allows for the design of reagents which recognize and bind to a particular domain or portion thereof, perhaps thereby modifying the activity of the receptor. Such reagents include, for example, various drugs and binding molecules. Binding proteins which have an affinity for the receptor protein include, for example antibodies, and preferably, monoclonal antibodies. Antisera raised to the purified scavenger receptor protein or a portion thereof, or antibodies purified from the antisera, can be prepared using well known protocols including injection of the purified protein or fragment, or analog thereof, preferably with Freund's adjuvant, into an appropriate mammalian host animal such as a rabbit, goat, or mouse. Preferably, however, monoclonal antibodies are prepared to the scavenger receptor protein, or active fragments of such antibodies, can be generated by applying generally known cell fusion techniques (cf. G. Kohler, C. Milstein, Vol. 6, Eur. J. Immunol., pp. 511-519 (1976); M. Shulman et al., Vol. 276, Nature, pp. 269-270 (1978)), herein incorporated by reference) to obtain a hybridoma producing the antibody, by deriving a monoclonal antibody from the hybridoma, and (optionally) by subjecting the monoclonal antibody to proteolysis to obtain an active fragment such as Fab.

For example, monoclonal antibodies can be prepared by obtaining mammalian lymphocytes (preferably mouse spleen cells), committing the lymphocytes to produce antibodies (e.g., by immunizing the mammal with the particular antigen of

-21-

interest beforehand), fusing the lymphocytes with myeloma (or other immortal) cells to form hybrid cells, and then culturing a selected hybrid cell colony in vivo or in vitro to yield antibodies which are derived from a single clone, and therefore, are identical in structure and specificity.

Alternatively, an antibody molecule of the appropriate specificity, or an active analog or fragments thereof may be produced synthetically in a protein synthesizer, or may be produced by recombinant means in genetically engineered cells.

Serum samples from the immunized animal can be taken and analyzed by an enzyme linked immunoabsorbent assay ("ELISA") or the like for antibody reaction with the immunization agent. Animals that exhibit antibodies titers are sacrificed and their spleens homogenized. Alternatively, the spleen cells can be extracted and the antibody-secreting cells expanded in vitro by culturing with a nutrient medium. The spleen cells are then fused with myeloma (or other immortal) cells. The hybridomas so produced are screened to select a cell line producing antibodies which react with the receptor protein. Large scale antibody production can be obtained from such receptor protein-producing cell lines by various techniques, including the induction of ascites tumors (e.g., after priming with pristane) and the purification of such antibodies from the ascites fluid by Protein A-Sepharose affinity chromatography.

For a further description of general hybridoma production methods, see, e.g., Oi and Herzenberg, "Immunoglobulin-Producing Hybrid Cell Lines" in Selected Methods in Cellular Immunology (Mishell and Shiigi, Ed., W.H. Freeman & Co., pp. 351-372 (1980); and Searce and Eisenbarth, "Production of Monoclonal Antibodies..." in Vol. 103, Methods In Enzymology, pp. 459-469 (1983), herein incorporated by reference. Human antibodies (i.e., those obtained from human-human or human-animal hybridoma) can be used as well as animal antibodies. For descriptions of human hybridoma production techniques, see, e.g., U.S. 4,451,570 issued to Royston et al; U.S. 4,529,694 issued to Lazarus et al.; and Zurawski et al., "Continuously Proliferating Human Cell Lines Synthesizing Antibody of Predetermining Specificity" in Monoclonal Antibodies (Plenum Press, New York (1980)), also incorporated by reference.

Active fragments can be derived from the monoclonal antibodies disclosed herein by a number of techniques. For example, purified monoclonal antibodies can be cleaved with a proteolytic enzyme such as pepsin, and then be subjected to HPLC gel filtration. The appropriate fraction containing the desired fragment such as, for example, an Fab fragment, can then be collected and concentrated by membrane filtration or the like. For further description of general techniques for the isolation of active fragments, see, for example, Khaw et al., Vol. 23, J. Nucl. Med., pp. 1011-1019 (1982), herein incorporated by reference.

The antibodies and fragments used herein can be labelled with radioactive tags such as radioisotopes by a variety of techniques. For example, the biologically active molecules can also be labelled with a radioisotope via conjugation with the cyclic anhydride of diethylenetriamine penta-acetic acid (DTPA) or bromoacetyl aminobenzyl ethylamine diamine tetra-acidic acid (BABE) (Hnatowich et al., Vol. 220, Science, pp. 613-615 (1983); and Meares et al., Vol. 142, Analytical Biochemistry, pp. 68-78 (1984), incorporated by reference).

The scavenger receptor protein and the binding proteins of the present invention can be used for a variety of diagnostic and therapeutic purposes. In a simple embodiment, soluble receptor proteins are harvested and purified from eucaryotic cells which are preferably mammalian, or from eucaryotic or prokaryotic cells engineered by recombinant means to produce such proteins, and used in both radiolabelled and unlabelled states in competitive binding assays to test for the presence of the receptor. The receptor protein, or fragments or analogs thereof, binding proteins thereto can also be fixed to inert supports for purification and assay purposes. For example, the collagen domain of the receptor protein can be linked to an inert support material for uses in affinity chromatographic methods to isolated lipids and lipid-containing substance such as endotoxin.

Various assay techniques can be practiced employing the reagents disclosed herein, including

radioimmunoassays, enzyme immunoassays, heterogeneous and homogeneous assays, enzyme linked immunoabsorbent assays ("ELISA"), and the like.

An exemplary assay for chemically modified LDL or other molecule with an affinity for the receptor protein ("analyte"), can be carried out as follows. The sample (having an unknown concentration of analyte) is first contacted with a known quantity of fixed receptor protein (or analog or a portion of the protein containing the epitope), during which time the analyte in the sample becomes bound to the receptor protein. The fixed support is then treated with a known quantity of radiolabelled analyte which binds to those sites on the fixed support which were unoccupied. Excess label is then washed off, and the quantity of label remaining on the support is inversely proportional to the amount of analyte originally present in the sample.

An alternative assay for analyte can be constructed using the receptor protein fixed to a solid support such as, for example, polystyrene beads or plastic microtiter wells. Samples containing analyte would be incubated with the receptor protein for a time sufficient for binding. The support is then washed to remove any unbound analyte. To detect the bound analyte, a developing reagent consisting of monoclonal or polyclonal antibodies reactive with radiolabelled or enzyme-linked analyte can be used. Alternatively, labelled receptor protein can also be employed. (See, e.g., Roitt, Essential Immunology, (Blackwell Press pp. 137-171 (1980), incorporated

-25-

her in by reference, for further descriptions of immunoassay techniques.

Fixation of receptor protein to solid supports can also be useful as a means for (or additional step in) the purification of crude chemically modified LDL. Similarly, the fixation of monoclonal antibodies specific for the receptor protein can be used in purifying the receptor protein, as well as in recognizing and isolating cells expressing the protein.

The present invention can give rise to a number of therapeutic agents useful in treating various vascular disorders. One class of such compounds includes antagonist compounds or binding reagents which would occupy the affinity sites on the macrophages and monocytes, blocking the binding of chemically modified LDL, and hence, serving as an inhibitor of foam cell development and plaque formation. Useful antagonist compounds include antibodies and preferably, monoclonal antibodies, (or active fragments, analogs, and derivatives thereof) specific for the receptor protein, itself, or portions of the protein (i.e. the extracellular domain) which include the chemically modified LDL binding site. Other useful antagonists include analogs of Ac-LDL or analytes which can bind to the receptor protein without triggering its morphogenesis to foam cells.

The receptor protein, or fragments thereof containing at least an extracellular domain, can also be useful as sequest ring agents which would remove

chemically modified LDL and other analytes from the blood stream without effecting macrophages, monocytes, or foam cells directly.

The receptor protein can also be useful in designing highly specific drug delivery systems to treat atherosclerosis. The ability of the receptor protein of the foam cell to endocytose various molecules can be exploited to deliver anti-viral agents, metabolites, anti-metabolites, and other therapeutic agents across the cytoplasmic membrane of the foam cell in the plaque. In such instances, the therapeutic agent would be coupled to a macromolecule that is recognized by the receptor protein, enabling the conjugate to become bound to, and ultimately endocytosed, by the foam cell in the plaque. Useful macromolecules for this purpose include Ox-LDL, Ac-LDL, and AcAc-LDL. A synthetic or genetically engineered macromolecule could also be employed.

An antagonist of the receptor protein may be useful in treating vascular disease. For example, a binding molecule such as an antibody, and more preferably, a monoclonal antibody with an affinity for the receptor protein can be administered to the vascular system of a subject. This antagonist will bind to the receptor protein found on plaque forming components such as macrophages, foam cells, and monocytes, thereby preventing or inhibiting such components from contributing to vascular disease such as developing (more) plaque. The antagonist may be any natural, biosynthetic, or synthetic molecule capable of binding and inhibiting the receptor prot in.

-27-

The invention will next be described in connection with certain illustrated embodiments. However, it should be clear that various modifications, additions and subtractions can be made without departing from the spirit or scope of the invention.

EXAMPLE 1

Scavenger receptor protein was purified from bovine tissue over 2,000-fold by a combination of maleyl-BSA affinity chromatography (M-BSA), hydroxyapatite chromatography (HAP), and preparative NaDodSO₄-polyacrylamide gel electrophoresis (SDS-PAGE) (TABLE 3, Method I). This procedure was performed at 4°C. Membrane proteins from 500 g of bovine liver were prepared essentially by the method of Schneider et al. (Vol. 225, *J. Biol. Chem.*, pp. 11442-11447 (1980)), herein incorporated as reference. The proteins were resuspended in 500 ml of 10 mM Tris-HCl, pH 8, 1 mM CaCl₂, 0.15 M NaCl and 1 mM PMSF (Buffer A). They were sonicated twice, and then dissolved by the addition of 55 ml of 20% Triton X-100 with stirring for 30 min. Insoluble material was removed by centrifugation (33,000 rpm, 1 hr, Beckman Type 35 rotor). The supernatant (500 ml) was applied at 75 ml/hr to an M-BSA-coupled Sepharose 4B column (Pharmacia, 9.8 x 12 cm, containing about 10 mg of M-BSA/ml of gel) which had been equilibrated with Buffer A containing 1% Triton X-100. The column was washed overnight with the same buffer and then washed with two column volumes of Buffer A containing 40 mM octylglucoside. The receptor protein was eluted

-28-

with Buffer B (1 M NaCl, 20 mM Tris HCl, pH 8, 1 mM CaCl₂, 1 mM PMSF, and 40 mM octylglucoside).

EXAMPLE 2

Filter binding and ligand blotting assays were performed with minor modification, according to the methods of Schneider et al. (*ibid.*) and Daniel et al. (Vol. 258, J. Biol. Chem. pp. 4606-4611 (1983)), respectively, herein incorporated as reference.

Ligand binding specificity was also determined by polynucleic acid affinity chromatography. M-BSA-purified proteins, having 150 ng of Ac-LDL binding activity in 4 ml of Buffer A containing 40 mM octyl glucoside, were applied to polynucleic acid coupled agarose columns (AG-POLY series, prepacked column, Pharmacia). After washing with the same buffer, the bound proteins were eluted with 5 ml of Buffer B.

Cellular scavenger receptor protein activity was assayed essentially as described by Krieger (Vol. 33., Cell pp. 413-422 (1983)), herein incorporated as reference, by measuring the degradation of ¹²⁵I-Ac-LDL (2 mg Ac-LDL protein/ml) in the presence or absence of inhibitor (M-BSA, 500 mg/ml).

EXAMPLE 3

The fractions obtained as described in EXAMPLE 1 were tested for their ability to bind Ac-LDL as described in EXAMPLE 2; those containing Ac-LDL binding activity (100 ml) were pooled and

-29-

concentrated (35 ml) using ultrafiltration (Diaflo membrane PM30, Amicon). The sample buffer was changed to 25 mM potassium phosphate, 40 mM octylglucoside, 1 mM PMSF, pH 6.8 using PD10 desalting columns (Pharmacia). The M-BSA affinity purified fraction (50 ml) was then applied to an Ultrogel-Ha (LKB) column (2.5 x 13 cm) at a flow rate of 75 ml/hr. The proteins were eluted with a gradient of phosphate buffer (25 mM to 350 mM) containing 40 mM octylglucoside.

The 220 kD protein was recovered at phosphate concentrations between 100 and 200 mM and was further purified by non-reducing SDS-PAGE on a 3-10% acrylamide gradient gel as described by Laemmli (Vol. 227, Nature pp. 680-685 (1970)), herein incorporated as reference). FIG. 1 shows the silver staining (A, lanes 1, 2, 3) and Ac-LDL ligand blotting (B, lanes 4, 5, 6) of the purified fractions on non-reducing gels. A 220 kD protein with Ac-LDL binding activity was purified. The protein was electroeluted from the gel in 0.1% SDS, 10 mM Tris-HCl, pH 8 using an ISCO 1750 electrophoretic concentrator. TABLE 3 summarizes these results under Method I.

TABLE 3

| <u>Protein</u> | | | | |
|------------------|-------------------|-------------------|---------------------------|----------------------|
| <u>Fraction</u> | <u>(mg/frac.)</u> | <u>total (mg)</u> | <u>Spec. Act. (mg/mg)</u> | <u>Pur. Fac. (X)</u> |
| <u>Method I</u> | | | | |
| Liver mem. | 21,580 | 107.9 | 0.005 | 1 |
| Maleyl-BSA | 72 | 154.8 | 2.15 | 430 |
| HAP Chrom. | 6 | 62.8 | 10.47 | 2094 |
| Prep. PAGE | 0.025* | -- | -- | -- |
| <u>Method II</u> | | | | |
| Lung mem. | 22,800 | 136.8 | 0.006 | 1 |
| M-BSA Chrom. | 45 | 121.0 | 2.684 | 427 |
| Immunoaff. | 0.03° | 42.0 | 14030 | 238,000 |

* Estimated from chromogeneity on silver staining of PAGE gels.

** Due to the presence of SDS, the activity could not be determined.

° Estimated from amino acid composition analysis.

Partial purification of the 220 kD protein from other bovine organs or from cells followed essentially the same procedure as for bovine liver, except that all steps were performed on a smaller scale.

The distribution of the 220 kD protein and Ac-LDL binding activity in various bovine organs was examined using immuno- and ligand blotting. There was close correlation of the intensities of staining and of the electrophoretic mobilities (220 kD) of the

antibody binding and ligand binding proteins. Ligand binding activities and the amounts of 220 kD protein were high in the liver, lung, spleen and adrenal gland, which are organs known to take up Ac-LDL efficiently in vivo. The intestine, which takes up little Ac-LDL, contained very little 220 kD protein and little binding activity.

EXAMPLE 4

The scavenger receptor protein was purified 238,000-fold by a combination of M-BSA affinity chromatography, and IgG-D1 immunoaffinity chromatography (TABLE 3, Method II). All procedures were performed at 4°C. 100 ml of Buffer C (0.1% SDS, 0.1% sodium deoxycholate, 1% Nonidet P40, 50 mM Tris-HCl, pH 8, 150 mM NaCl, and 1 mM PMSF) were added to M-BSA affinity purified proteins from 500 g of bovine liver or lung in 100 ml Buffer B. The sample was applied to Sepharose 4B (Pharmacia) coupled with IgG-D1 prepared as described below. (4 mg antibody/ml gel, 1 x 2 cm) at a flow rate of 50 ml/hr, and recycled overnight. The column was washed consecutively with 50 ml of Buffer C, 50 ml of Buffer D (0.2% Triton X-100, 10 mM Tris-HCl, pH 8), 50 ml of Buffer D containing 2 M NaCl, and 20 ml of Buffer E (40 mM octylglucoside containing 10 mM Tris-HCl, pH 8). The bound proteins were then eluted with 20 ml of Buffer E containing 2 M guanidine thiocyanate. After elution, the buffer was changed to Buffer A containing 40 mM octylglucoside using PD10 columns (Pharmacia). Proteins were stored at -70°C. TABLE 3 summarizes the results under Method II.

EXAMPLE 5

A hybridoma was made by the fusion of mouse myeloma cells (P3X63-Ag8.653) and spleen cells of a mouse which had been immunized with receptor protein purified by preparative SDS-PAGE, essentially as described by Oi et al. (ibid.), herein incorporated as reference. 15 mg of receptor protein was used for the initial injection, and 10 mg was used for the booster. Hybridomas secreting antibody were identified by an enzyme immunoassay using 96-well plates coated with hydroxyapatite (HAP)-purified proteins as described by Beisiegel et al. (Vol. 256, J. Biol. Chem. pp. 11923-11931 (1981)), incorporated herein as reference, and then by immunoblotting as described by Tsang et al. (Vol. 92, Methods in Enzymology pp. 377-390 (1983)), incorporated herein as reference. The hybridomas were subjected to limiting dilution twice and were cultivated in RPMI 1640 medium containing 0.1% fetal calf serum and 1% Nutridoma-NS. The monoclonal antibody IgG-D1, and the control antibody which recognizes a distinct and apparently unrelated 287 kD protein, were isolated from the culture media by Affigel protein A chromatography using a MAPS II buffer kit (Bio Rad).

EXAMPLE 6

Partially purified receptor protein isolated as described in EXAMPLE 1 was subjected to SDS-PAGE and immunoblotting procedures as described by Tsang et al., (ibid.). The immunoblot shown in FIG. 1(C), (lane 7) demonstrates that IgG-D1, raised against the

-33-

unreduced, gel-purified 220 kD bovine protein, recognizes the bovine 220 kD protein. Reduction abolishes the binding of IgG-D1 and Ac-LDL ligand blotting activity.

EXAMPLE 7

The cell type specificity and tissue distribution of the 220 kD protein and its relation to the Ac-LDL receptor were also studied using immunochemical techniques. Immunoprecipitation was performed essentially as described by Kozarsky et al. (Vol. 102, J. Cell Biol., pp. 1567-1575 (1986)), herein incorporated as references using the monoclonal antibodies obtained as described in EXAMPLE 3, and using the HAP-purified binding protein from bovine liver or lung (2-10 mg Ac-LDL binding activity/mg protein) which had been radioiodinated using Iodobeads (Pearce). The results of immunoprecipitation of ^{125}I -labelled specimens with IgG-D1 or with control antibody T2D2 are shown in FIG. 5. IgG-D1 specifically precipitated three ^{125}I -labelled bovine species with apparent molecular weights of 220 kD, 150 kD, and 77 kD (FIG. 5A, lane 1). The immunoprecipitated 220 kD protein was recovered and shown to retain Ac-LDL binding activity by ligand blotting (FIG. 5B, lane 5).

EXAMPLE 8

The scavenger receptor proteins precipitated by IgG-D1 and purified by immunoaffinity chromatography exhibited apparent molecular weights of 220 kD, 150 kD, and 77 kD by non-reducing

SDS-PAGE. After reduction they collapsed into 77 kD bands (FIG. 5A, lanes 3 and 4). When the 220 kD and 150 kD proteins, obtained by immunoprecipitation or immunoaffinity chromatography, were individually recovered from preparative gels and then reduced, the apparent mass of each was also converted to 77 kD, indicating that the 220 kD and 150 kD proteins were trimers and dimers of 77 kD subunits.

The carbohydrate characteristics of the receptor protein were determined by subjecting the 77,000 dalton subunit to immunoprecipitation (as described in EXAMPLE 7) followed by digestion with sialidase (Boehringer Mannheim, Indianapolis, Indiana) or endoglycosidase F (GENZYME, Boston, MA) as described by Elder et al. (Vol. 79, Proc. Natl. Acad. Sci. (USA), pp. 4540-4544 (1982)) herein incorporated as reference. The resulting protein was then subjected to SDS-PAGE under reducing conditions (FIG. 6). After treatment, its apparent molecular weight was reduced by approximately 5 kD after sialidase treatment, or 13 kD after endoglycosidase treatment, demonstrating the presence of asparagine-linked carbohydrate chains and sialic acids.

The immunoaffinity-purified activity also exhibited apparent molecular weights of 220 kD, 150 kD, and 77 kD by non-reducing SDS-PAGE (FIG. 5C, lane 7).

EXAMPLE 9

Immunohistochemistry was performed on bovine liver samples as follows. Tissue sections (6 mm) were cut on a cryostat at -20°C, placed on glass slides, air dried for 1 hour, and fixed in cold 95% methanol. The sections were incubated with monoclonal antibody IgG-D1 (6 mg/ml) or control mouse IgG. The binding of IgG was visualized using peroxidase-conjugated sheep anti-mouse IgG Fab by 3,3'-diaminobenzidine tetrahydrochloride staining as described by Adamson et al., (Vol. 130, J. Immunol. pp. 203-207 (1983)), herein incorporated as reference. Sections were counterstained with methyl green (Sigma).

FIG. 7 shows the immunohistochemical analysis of frozen liver sections using the anti-bovine 220 kD protein monoclonal antibody IgG-D1. The distribution of the 220 kD binding protein matches that previously described for scavenger receptor protein activity: specific sinusoidal (arrows), but not hepatocyte (H), immunostaining (panels B and C); and very little staining in the area immediately surrounding the central vein (CV). P indicates portal area.

EXAMPLE 10

Cell cultures of macrophages were prepared to test their ability to take up acetyl-LDL. Bovine alveolar macrophages were collected from fresh lung by bronchial lavage with phosphate buffered saline (PBS, 1 liter/lung). They were cultivated with RPMI

1640 medium containing 10% fetal calf serum for 6 hrs at 37°C in a CO₂ incubator, and washed with PBS 6 times to remove non-adherent cells. The uptake of fluorescent Ac-LDL labelled with 1,1'-dioctadecyl-3,3,3',3'-tetramethyl-indocarbocyanine (DiI) was performed as described by Kingsley et al. (Vol. 81, Proc. Natl. Acad. Sci. (USA) pp. 5454-5458 (1984)), herein incorporated as reference.

For immunoblotting, cells from two 150 mm dishes were incubated with trypsin (0.05%) or PBS for 5 min at 37°C, and harvested by scraping. Floating cells were recovered by centrifugation and were mixed with the scraped cells. The cells were then resuspended in 10 ml of ice cold Buffer A. The 220 kD protein, partially purified from the membrane using M-BSA affinity chromatography, was subjected to immunoblotting as described in EXAMPLE 6. The viability of cells, determined by either trypan blue staining (floating cells) or restoration of DiI-Ac-LDL uptake after overnight cultivation (adherent cells), was not significantly affected by the mild trypsin digestion.

Coincident expression of Ac-LDL receptor activity (fluorescent DiI-Ac-LDL accumulation, FIG. 8 panel A) and the 220 kD protein (immunoblotting with IgG-DI, FIG. 8, panel B, lane A) was also detected in cultured bovine alveolar macrophages. Fluorescently labelled Ac-LDL uptake was blocked by the presence of excess unlabelled Ac-LDL (panel A). Immunodetection of the 220 kD protein was prevented by pretreating the macrophages with low, sublethal levels of trypsin

-37-

(0.05%) for 5 min. at 37°C (FIG. 8, panel B, lan B). The trypsin sensitivity of this protein in intact cells suggests that some of the 220 kD protein is at least partially exposed at the cell surface.

EXAMPLE 11

The human monocytic leukemia cell line THP-1 was cultivated in RPMI 1640 medium containing 10% fetal calf serum. THP-1 cells were induced to differentiate into macrophage-like cells by cultivation for 3 days in the presence of 200 nM phorbol 12-myristate 13-acetate (PMA). The maleyl-BSA affinity purified membrane proteins from 10^8 cells treated with or without PMA were subjected to Ac-LDL ligand blotting and filter binding assays as described in EXAMPLE 1.

Coincident and coordinately regulated expression of acetyl-LDL receptor activity and a 220 kD binding protein were observed in this human cell line. FIG. 9 shows that the phorbol ester induction of receptor activity (^{125}I -Ac-LDL degradation assay) is accompanied by a substantial increase in the ^{125}I -Ac-LDL binding activity of cell membrane proteins (filter binding assay), and by a dramatic increase in the amount of activity of a 220 kD scavenger receptor protein (ligand blot assay). The immunoaffinity-purified receptor protein bound ^{125}I -Ac-LDL with an apparent dissociation constant of 0.5 mg/ml (0.8 nM) (FIG. 10A). The maximum binding of ^{125}I -Ac-LDL was about 1.4 mg/mg.

Competition of Ac-LDL binding was measured by preincubating immunoaffinity purified receptor protein/phospholipid complexes in the various concentrations of analyte competitors for 30 min. prior to the addition of ^{125}I -Ac-LDL (2 mg protein/ml) for 1 hour at 4°C . (Relatively successful analyte competitors were LDL, maleyl-BSA, fucoidan, polyvinylsulfate, and the purine polynucleotides poly[I], poly[I-C], and poly[G] (FIG. 10B).

The purified receptor can also bind Ox-LDL. TABLE 4 demonstrates this activity. The Ox-LDL was prepared using the method of Steinbrecher et al. (Vol. 81, Proc. Natl. Acad. Sci (USA) pp. 3883-3887 (1984)), herein incorporated as reference. The specific activity was determined by subtracting the binding activity in the presence of competitor (200 $\mu\text{g/ml}$ Ac-LDL) from the activity in the absence of competitor by the liposome reconstitution assay using ^{125}I -Ox-LDL. These results indicate that the scavenger receptor protein may also play an important role in the metabolism of Ox-LDL.

TABLE 4

| <u>Oxidized-LDL</u> (mg/ml) | <u>Specific Binding of ^{125}I-Ox-LDL</u> (μg Ox-LDL/mg scavenger receptor) |
|--------------------------------|--|
| 0.5 | 59 |
| 1.0 | 89 |
| 2.0 | 135 |
| 5.0 | 302 |
| 10.0 | 417 |

EXAMPLE 12

The scavenger receptor protein was further purified using RP-300 (Brownlee Laboratory, Emeryville, CA) reverse phase HPLC. The receptor was solubilized in 70% formic acid. It was then cleaved by cyanogen bromide (CNBr) (25 mg/100 ml solution) at room temperature, overnight, resulting in the formation of a number of cleavage fragments. The fragments were chromatographically separated on the RP-300 column.

One of the fragments was isolated and subjected to automated amino acid analysis using an Applied Biosystems amino acid sequencer (Foster City, CA). The following amino acid sequence was thereby obtained:

Arg-Ile-Gln-Tyr-Leu-Ser-Asp-Asn-Glu-Ala-
Asn-Leu-Leu-Asp-Ala-Lys-Asn-Phe-Gln.

A second sequence (below) was obtained from a similar CNBr digestion using the gel electrophoresis/immunoblotting method of Matsudaira (J. Biol. Chem. (1987) 262:10035-10038):

Lys-Leu-Leu-Asn-X-Ile-X-Asn-Asp-Leu-Arg-Leu-X-Asp-Trp

where "X" indicates that the amino acid residue at that position is uncertain. (See FIGs. 3A-C for the relative location of these residues (underscored dots) in the amino acid sequence of clone 3.)

EXAMPLE 13

Methodology for the development and identification of the clones, unless otherwise noted, were standard procedures such as those described in Maniatis et al. (Molecular Cloning, A Laboratory Model (1982) Cold Spring Harbor Laboratory) and Davis et al. (Basic Methods In Molecular Biology (1988) Elsevier Scientific Publishing Co., Inc., NY).

A. Preparation of cDNA Libraries

Poly(A)⁺ mRNA was isolated by acid guanidium thiocyanate/phenol/chloroform extraction as described by Chomczynski (Anal. Biochem. (1987) 162:156) from bovine lung, and was used to construct a random primed cDNA library. 6 µg of bovine lung macrophage mRNA and 5 µg of random hexanucleotides were used to synthesize double-stranded cDNA following the general procedure of Gubler and Hoffman (Gene (1983) 25:263). The cDNA so synthesized was ligated to Eco R1 adaptors (Pharmacia), and was then size-fractionated on a 5-20% potassium acetate gradient by centrifugation for 3 hr in an SW60 rotor (Beckman Instruments) at 50,000 rpm. The cDNA fractionating at molecular masses of approximately greater than or equal to 800 base pairs (by agarose electrophoresis) was then ligated into Eco R1 digested λzap (Stratagene), packaged, and subsequently used to infect XL-1 Blue cells (Stratagene). 1.5 x 10⁶ primary clones were obtained and amplified.

A human cDNA library was prepared from the human monocytic leukemia cell line THP-1 using equivalent methodologies.

B. Library Screening and Isolation of cDNA Clones

The bone and human libraries were screened with two pools of 41mer oligonucleotide probes that included 5-fluorodeoxyuridine (F) (Habener et al. (1988) Proc. Natl. Acad. Sci. (USA) 85:1735-1739) according to the amino-acid sequence:

RIQULNSDNEANLLDA.

These pools were divided according to the codon usage at serine. Pool I contained:

5'-ATFCAGTAFFT(F/G)TC(F/G)GAFAAFGA
GGCF/G)AAFFT(F/G)FT(F/G)GAGAFGC-3'.

Pool II contained AGF at the underlined (TC(F/G)) nucleotides shown above for pool I. For each pool, 5×10^5 plaques were screened using ^{32}P end-labelled probes by hybridization at 37°C and washing at 50°C in 6 x SSC (Maniatis et al. ibid. pp. 447) with 0.1% SDS. Putative positive clones were purified and in vivo excised into picobule (pBluscript)-derived plasmids (Short, ibid.). The inserts were screened by Southern blot hybridization (Southern (1975) J. Mol. Biol. 98:503) using 4 pools of the 17mer oligonucleotide:

A(A/G)(A/G)TTNGC(C/T)TC(A/G)TT(A/G)TC,

-42-

each containing a different nucleotide at the underlined (N) position. Pool III contained:

AT(F/A)CA(G/A)TAFFTTTCTGAFAAFGA(G/A)GC

and pool IV contained AGF at the underlined (TC) position of pool III.

Five positive bovine clones were selected and sequenced according to the Sanger method (Sanger et al. (1977) Proc. Natl. Acad. Sci. (USA) 74:5463). These clones have a nucleotide sequence corresponding to the peptide sequence. FIGs. 3A-C show the nucleic acid sequence and corresponding deduced amino acid sequence of clone 3, while FIGs. 4A-D show a composite nucleic acid sequence and corresponding deduced DNA sequence of clones 7, 12, and 13. The human cDNA library was also screened with probes derived from the bovine cDNA using equivalent methodology. FIGs. 14A-B show the nucleic acid sequence and correspondingly deduced amino acid sequence derived from human clones.

C. Sequence Analysis

The sequencing of the cDNA bovine clones indicates that the cDNAs isolated are derived from two different mRNAs. Both of these mRNAs encode identical 347 amino acid N-terminal domains [Met¹ → ARG³⁴⁷]. They differ in this region by one nucleic acid which does not result in an amino acid change. The two mRNAs begin to differ at amino acid position 348. The sequence of clone 3 (FIGs. 3A-C) continues for only 2 additional amino acids before a

-43-

stop codon is seen. (Arg-Pro-Gly STOP). In contrast, the sequence of clone 7 (FIGs. 4A-D) continues for an additional 106 amino acids.

Clone 3 contains 35 noncoding bases at its 5' end, 1047 bases of coding region, and 965 noncoding bases at its 3' end (FIGs. 3A-C). In coding region (* denotes the start of the coding region), amino acid residues 1-50 represent the cytoplasmic domain (Cy), residues 51-76 represent the proposed transmembrane domain (TM), residues 77-271 represent the proposed Asn-linked sugar domain, residues 272-343 represent the proposed collagen domain (Col), and residues 344-349 represent the proposed C-terminal domain (C-term). In FIGs. 3A-C, the residues of the TM domain are underscored (first underscored region); the Asn-linked sugar sites are overscored; the Col domain is underscored (second underscored region); M* is the initiator Met; and the first 19 amino acids making up the peptide used to generate the anti-peptide antibody are underscored with dots (with the exception of Ser¹³⁸, which was later determined to be Lys).

Clone 7 (FIGs. 4A-D) has no 5' noncoding bases, 1359 bases of coding region, and 211 noncoding bases at its 3' end.

D. Expression of cDNA Clones

A clone 3 expression vector pXAxLDLR3 was prepared by excising the clone 3 sequence from the pBluescript product (i.e., the in vivo excision product of the λ zap vector) using BAM H1 and Xho1.

-44-

The resulting DNA fragment was then ligated into the pcDNA1 plasmid (Invitrogen) which had been previously cut with the same restriction enzymes.

On day 0, monkey COS M6 cells (derived from COS 7 cells available from the American Type Culture Collection, Rockville, MD, and a gift from D. Hausman, Dept. of Biology, MIT) were set at 1.5×10^6 cells/100 mm dish in the standard cell culture medium DMEM (Gibco) containing 10% fetal bovine serum, penicillin, and streptomycin. On day 1, the cells were transfected following standard procedures (Seed et al. (1987) Proc. Natl. Acad. Sci. (USA) 84:3365-3369). In brief, a transfection cocktail was added to each dish already containing 4 ml DMEM containing 10% Nuserum (Collaborative Research). The cocktail consisted of 10 μ l (40 mg/ml) DEAE Dextran solution, (Pharmacia), 40 μ l of 10 mM chloroquine (Sigma), and 4 μ g clone 3 expression vector pXACDLR3. The final concentrations in the transfection medium were 10% NuSerum, 100 μ g/ml DEAE Dextran, 100 μ M chloroquine, and 4 μ g/ml vector DNA. After incubation for 4 hr at 37°C, the transfection medium was removed and the cells treated for 2 min with Hepes buffered saline (HBS: 137 mM NaCl, 5 mM KCl, 0.7 mM Na₂HPO₄, 6 mM dextrose, 21 mM Hepes, pH 7.1) containing 10% dimethylsulfoxide (DMSO). The HBS-DMSO solution was removed and the cells refed with standard culture medium (DMEM containing 10% fetal bovine serum and the antibiotics). On day 2, the transfected cells were harvested by trypsin treatment. They were reset into 6-well dishes at a concentration of 1×10^6 per well for assays

-45-

performed on day 4, or at a concentration of 0.8×10^6 per well for assays performed on day 5.

E. Receptor Activity Assay

The ability of the transfected monolayers to degrade 5 μ g protein/ml of ^{125}I -Ac-LDL in the absence (triplicate determinations) or presence (single determinations) of different concentrations of various unlabeled competitors was measured using the standard assay procedures of Krieger (*ibid.*).

The results are shown in FIG. 11. In control cells transfected with pcDNA which did not contain clone 3, the amount of Ac-LDL degraded was only 5% of that degraded by the pAcLDL3-transfected cells. This experiment demonstrates that high affinity Ac-LDL receptor activity is expressed in cells transfected with an expression vector including clone 3 (pXAcLDLR3).

In another experiment, cells were prepared and assays were performed as described above except that 400 μ g/ml competitor was used. The inhibitors included poly [I], poly [C], LDL, Ac-LDL, maleylated bovine serum albumin (M-BSA), Ox-LDL, BSA, and polyvinyl sulfate (PVS). The results are shown in FIG. 12. This experiment also indicates that clone 3 can express high affinity Acetyl-LDL receptor activity in cells transfected with the clone 3-containing vector pXAcLDLR3.

F. Tissue and Cell Type-Specific Expression of Ac-LDL Receptor mRNA

The ability of Ac-LDL encoding-clones to be expressed in different cell and tissue types was investigated to determine if the pattern of their expression mirrored that of the expression of the native receptor. Standard Northern (RNA) blot hybridization methods were followed using the collagen domain-encoding fragment of clone 3 as a probe. THP-1 cells were cultivated with or without 200 nM phorbol 12-myristate 13-acetate (PMA) for 3 days to induce them to differentiate into macrophage-like cells (Kodama et al. (1988) Proc. Natl. Acad. Sci. (USA) 85:9238 (Dec.)). Bovine alveolar macrophages were prepared as previously described (Kodama, *ibid.*). Poly(A)⁺ RNA (3 µg) from these cells and from various bovine organs was isolated and blotted on a cellulose nitrate membrane. The Xba 1/Sph 1 fragment of a subclone pJAL 5, which includes the sequence encoding the collagen-like domain of clone 3, was 32p radiolabelled, hybridized at 42°C in the presence of 40% formamide, and washed with 2 x SSC containing 0.1% SDS at 55°C.

The results are shown in FIG. 13(A). RNA sequences encoding the Col domain are detected in THP-1 PMA(+) (differentiated) macrophages as well as in alveolar macrophages and lung. This pattern of RNA expression is the same as the pattern of in vivo receptor expression.

-47-

To simultaneously determine the amount of receptor activity in the same tissue specimens, receptor protein was purified from these bovine tissues (5 g per organ). The tissue was homogenized, maleyl-BSA-affinity purified, and subjected to immunoblotting using monoclonal anti-bovine receptor antibody IgG-D1 as described previously (Kodama, ibid.).

The results of this immunoblotting analysis are shown in FIG. 12(B). Receptor was detected in lung, but not in brain or muscle, as expected from the Northern blot results described above.

It can be seen from the foregoing description and examples that a receptor protein having a high affinity for Ac-LDL can be isolated and purified to near homogeneity from various appropriate mammalian tissues. Monoclonal antibodies can be made to this receptor protein which can aid in its identification and further purification, and which are useful in methods of detecting cellular structures that contain the receptor protein such as atherosclerotic plaques. In addition, DNA clones can be prepared which encode at least a portion of the scavenger receptor protein, and that these clones have the same pattern of differential expression in various tissue types as does the native receptor. Furthermore, the expressed protein has scavenger receptor protein-like activity.

The invention may be embodied in other specific forms without departing from the spirit or

essential characteristics thereof. The present embodiments are therefore to be considered in all respects as illustrative and not restrictive, the scope of the invention being indicated by the appended claims rather than by the foregoing description, and all changes which come within the meaning and range of equivalency of the claims are therefore intended to be embraced therein.

We claim:

1. A substantially pure receptor protein capable of binding acetylated low density lipoprotein, said protein characterized by:
 - having an apparent molecular weight on SDS-polyacrylamide gels of about 220,000 daltons; and
 - having an affinity for acetylated low density lipoprotein.
2. An active fragment, analog, or derivative of said receptor protein of claim 1 capable of binding acetylated low density lipoprotein.
3. The receptor protein of claim 1 further characterized as being a glycoprotein.
4. The receptor protein of claim 3 further comprising an asparagine-linked carbohydrate chain.
5. The receptor protein of claim 1 further characterized as comprising a trimer of subunits, each of said subunits having an apparent molecular weight on polyacrylamide gels of about 77,000 daltons.
6. The receptor protein of claim 5 wherein each of said subunits comprises an asparagine-linked carbohydrate chain.
7. The receptor protein of claim 1 further characterized by having an affinity for acetylated low density lipoprotein of about 0.5 micrograms per milliliter.

8. The receptor protein of claim 1 further characterized by the ability to bind a negatively charged macromolecule selected from the group consisting of polyvinylsulfate, maleyl-BSA, fucoidan, and purine polynucleotides, poly[I-C], poly[I] and poly[G].

9. A binding reagent characterized by having the ability to bind the scavenger receptor protein, said receptor protein being characterized by having an apparent molecular weight on polyacrylamide gels of about 220,000 daltons, and having an affinity for acetylated low density lipoprotein.

10. The binding reagent of claim 9 where said reagent is a biologically active molecule selected from the group consisting of antibodies, fragments, analogs, and derivatives thereof retaining the ability to react with said scavenger receptor protein.

11. The binding reagent of claim 9 further comprising monoclonal antibodies.

12. The binding reagent of claim 9 further comprising a labelling means.

13. The antibody of claim 12 wherein said labelling means comprises a radioisotope.

-51-

14. A device for assay or purification purposes, said device comprising:
- a support; and
 - a plurality of binding reagents bound to said support, each of said binding reagents being characterized by having the ability to bind acetylated low density lipoprotein.
15. The device of claim 14 wherein each of said reagents is a biologically active molecule selected from the group consisting of antibodies, fragments, analogs, and derivatives thereof retaining the ability to react with said scavenger receptor protein.
16. The device of claim 15 wherein said reagents comprise monoclonal antibodies.
17. A device for assay or purification purposes, said device comprising:
- a support; and
 - a plurality of receptor proteins bound to said support, each of said receptor proteins being characterized by having an apparent molecular weight on polyacrylamide gels of about 220,000 daltons, and the ability to bind acetylated low density lipoprotein.
18. The device of claim 17 wherein said receptor proteins are selected from the group consisting of active fragments, analogs, and derivatives of said receptor protein capable of binding oxidized low density lip protein.

19. A method of detecting an atherosclerotic plaque in the vascular system of a subject, said method comprising the steps of:

coupling a binding agent to a labelling means to form a conjugate, said binding agent having a specific affinity for a scavenger receptor protein associated with a macrophage, said macrophage being associated with said plaque;

administering said conjugate to the vascular system of said subject;

allowing said binding agent of said conjugate to bind to said scavenger receptor protein; and

detecting the presence and location of said labelling means of said conjugate in the vascular system of said subject.

20. The method of claim 19 wherein said coupling step includes coupling said labelling means to a binding reagent selected from the group consisting of antibodies, fragments, analogs, and derivatives thereof, each of said group retaining the ability to react with said scavenger receptor protein.

21. The method of claim 20 wherein said coupling step further comprises coupling said labelling means to a monoclonal antibody.

22. The method of claim 19 wherein said coupling step further comprises coupling said binding reagent to a radioisotope, and said detecting step comprises detecting said radioisotope by extracorporeal radioactivity-detecting means.

23. A method of selectively delivering a therapeutic agent to an atherosclerotic plaque in the vascular system of a subject, said method comprising the steps of:

coupling a therapeutic agent to a binding agent to form a conjugate, said binding agent having a specific affinity for a scavenger receptor protein on a plaque-forming component associated with said plaque; and

administering said conjugate to the vascular system of said subject, said conjugate binding to said receptor protein, thereby delivering said therapeutic agent to said plaque-forming component and said plaque.

24. The method of claim 23 wherein said coupling step further comprises coupling said therapeutic agent to a binding agent, said binding agent including oxidized low density lipoprotein.

25. The method of claim 23 wherein said coupling step further comprises coupling said therapeutic agent to a binding agent, said binding agent including acetylated low density lipoprotein.

26. The method of claim 23 wherein said coupling step further comprises coupling said therapeutic agent to a binding agent, said binding agent including an antibody having a specific affinity for said scavenger receptor protein.

27. The method of claim 26 wherein said coupling step further comprises coupling said therapeutic agent to a binding agent, said binding agent including a monoclonal antibody.

28. The method of claim 26 wherein said coupling step further comprises coupling said therapeutic agent to a binding agent selected from the group consisting of antibodies, fragments, analogs, and derivatives thereof, each of said group retaining the ability to react with said scavenger receptor protein.

29. A method of treating vascular disease comprising the steps of:

administering to the vascular system of a subject a therapeutic agent, said agent including an antagonist of the scavenger receptor protein; and

allowing said antagonist to bind to said receptor protein on a plaque forming component so as to inhibit the contribution of such plaque forming component to vascular disease.

30. The method of claim 29 wherein said administering step comprises administering a binding molecule to the vascular system, said binding molecule having a specific affinity for said receptor protein.


31. The method of claim 30 wherein said administering step further comprises administering a binding molecule to the vascular system, said binding molecule including an antibody having a specific affinity for said receptor protein.


32. The method of claim 31 wherein said administering step comprises administering an antibody to the vascular system, said antibody including a monoclonal antibody having a specific affinity for said receptor protein.

33. A polypeptide comprising an amino acid sequence sufficiently duplicative of the amino acid sequence of at least one subunit of the scavenger receptor protein such that the polypeptide, when combined with one or more additional polypeptides or native subunits of said scavenger receptor protein, binds chemically modified forms of LDL.

34. A DNA sequence comprising a sequence encoding at least a portion of the protein of claim 1 or 2.

35. A DNA sequence comprising a sequence encoding at least a portion of the polypeptide subunit of claim 33.

**FIG. 1**

**FIG. 2**

1
 TAAATCGGTGCTGCCGTCTTTAGGACATATGAAGTATGGCACAGTGGGAT 50
 1 5
 M* A Q W D
 51
 GACTTTCCTGATCAGCAAGAGGACACTGACAGCTGTACAGAGTCTGTGAA 100
 6 22
 D F P D Q Q E D T D S C T E S V K
 101
 GTTCGATGCTCGCTCAGTGACAGCTTTGCTTCCTCCCCATCCTAAAAATG 150
 23 39
 F D A R S V T A L L P P H P K N G
 151
 GCCCAACTCTTCAAGAGAGGATGAAGTCTTATAAAACTGCACTGATCACC 200
 40 55
 P T L Q E R M K S Y K T A L I T
 201
 CTTTATCTCATTGTGTTTGTAGTTCTCGTGCCCATCATTGGCATAGTGGC 250
 56 72
L Y L I V F V V L V P I I G I V A
 251
 AGCTCAGCTCCTGAAATGGGAAACGAAGAATTGCACGGTTGGCTCAGTTA 300
 73 89
A O L L K W E T K N C T V G S V N
 301
 ATGCAGATATATCTCCAAGTCCGGAAGGCAAAGGAAATGGCAGTGAAGAT 350
 90 105
 A D I S P S P E G K G N G S E D
 351
 GAAATGAGATTTTCGAGAAGCTGTGATGGAACGCATGAGCAACATGGAAAG 400
 106 122
 E M R F R E A V M E R M S N M E S
 401
 CAGAATCCAGTATCTTTCAGATAATGAAGCCAATCTCCTAGATGCTAAGA 450
 123 139
 R I Q Y L S D N E A N L L D A K N

FIG. 3A

451 500
 ATTTCCAAAATTTTCAGCATAACAACCTGATCAAAGATTTAATGATGTTCTT
 140 155
 F Q N F S I T T D Q R F N D V L
 . .

501 550
 TTCCAGCTAAATTCCTTACTTTTCTCCATCCAGGAACATGAGAATATCAT
 156 172
 F Q L N S L L S S I Q E H E N I I

551 600
 AGGGGATATCTCCAAGTCATTAGTAGGTCTGAACACCACAGTACTTGATT
 173 189
 G D I S K S L V G L N T T V L D L

601 650
 TGCAGTTCAGTATTGAAACACTGAATGGCAGAGTCCAAGAGAATGCATTT
 190 205
 Q F S I E T L N G R U Q E N A F

651 700
 AAACAACAAGAGGAGATGCGTAAATTAGAGGAGCGTATATACAATGCATC
 206 222
 K Q Q E E M R K L E E R I Y N A S

701 750
 AGCAGAAATTAAGTCTCTAGATGAAAAACAAGTATATTTGGAACAGGAAA
 223 239
 A E I K S L D E K Q U Y L E Q E I

751 800
 TAAAAGGGGAAATGAAACTGTTGAATAATATCACTAATGATCTGAGGCTG
 240 255
 K G E M K L L N N I T N D L R L

801 850
 AAGGATTGGGAACATTCTCAGACATTGAAAAATATCACTTTACTCCAAGG
 256 272
 K D W E H S Q T L K N I T L L Q G
 . .

851 900
 TCCTCCTGGACCTCCAGGTGAAAAAGGAGATAGAGGCCCTCCTGGACAAA
 273 289
P P G P P G E K G D R G P P G O N

FIG. 3B

901 950
ATGGTATACCAGGCTTTCCAGGTCTAATAGGTACTCCAGGTCTTAAAGGT
290 305
G I P G F P G L I G T P G L K G

951 1000
GATCGGGGGATCTCTGGTTTACCTGGAGTTCGAGGATTCCCAGGACCAAT
306 322
D R G I S G L P G V R G F P G P M

1001 1050
GGGGAAGACCGGGAAGCCAGGACTTAATGGACAAAAAGGCCAGAAGGGAG
323 339
G K T G K P G L N G O K G O K G E

1051 1100
AAAAAGGGAGTGGAAGCATGCAAAGACCAGGATAACTCCCTGATCGTATT
340 349
K G S G S M Q R P G *

1101 1150
AGGCAGGCCCTTTGAAGATCAGGTGGGTTGGGCGGGACACCCCGTGCTA
1151 1200
CCATCTCATTAAAAGGCCCTTCATCTCTGGACAAGTCATCAGCCACATCT
1201 1250
GACTCCAGGATTCCCTTGTGGCTCCTCCAAACCGACCTTGGTTCCCACGT
1251 1300
GGTGTGAGCTACCTGTCCGCTCTCCAGCACCTCTCCATGACCACTGTCCC
1301 1350
TGAGCTGGGATGCCTCCATGACTCACTCATCTAGTGTCTCCCGAATCATT
1351 1400
GGCTCCCAGGAGAAATTTTCATGGTAACAGATTATATGTGAGTTCTTTACC
1401 1450
CTCAAACATATCAGTCTCAGCCAGAGATAGTGATGCCATACAGCTAATAA
1451 1500
GATAGCTGTTGTCTCTGGCCTTCCAGAACTAATTGTCCCTGAAAAACATA
1501 1550
GCCATGGACACAAGCAGTTATGCATTAGAGCAGGGCTAGATGGGGGAAGG
1551 1600
AACTGGGCTCCGTGGGTGTTTCAGAGGGGATCAAGAGTCTTCAATTCCTTA
1601 1650
GAATTTTAAAAAGGTAAATTCAAGTTTTTGTGATGAAGTCAAGTGGAGCTG
1651 1700
GGGCAGTTCCTTCAAATTTTTTAGCCAAAAAAAAAAAAAAAAATCAAATTT
1701 1750
GTTGCCTTAAATTACCAGGCTCTTTCAAGCAAGAATATTTTGACCATAAA
1751 1800
AAAATAATGCTGAAACTATTTTATTCTATAAAGCTCTTTTCACCAGCCCT
1801
CGTGCCG

FIG. 3C

126 170
 AGTATGGCACAGTGGGATGACTTTCCTGATCAGCAAGAGGACACTGACAG
 1 16
 M* A Q W D D F P D Q Q E D T D S

 173 220
 CTGTACAGAGTCTGTGAAGTTCGATGCTCGCTCAGTGACAGCTTTGCTTC
 17 33
 C T E S V K F D A R S V T A L L P

 223 270
 CTCCTCATCCTAAAAATGGCCCAACTCTTCAAGAGAGGATGAAGTCTTAT
 34 49
 P H P K N G P T L Q E R M K S Y

 273 320
 AAAACTGCACTGATCACCCCTTATCTCATTGTGTTTGTAGTTCTCGTGCC
 50 66
 K T A L I T L Y L I V F V V L V P

 323 370
 CATCATTGGCATAGTGGCAGCTCAGCTCCTGAAATGGGAAACGAAGAATT
 67 83
 I I G I V A A Q L L K W E T K N C

 373 420
 GCACGGTTGGCTCAGTTAATGCAGATATATCTCCAAGTCCGGAAGGCAAA
 84 99
 T V G S V N A D I S P S P E G K

 423 470
 GGAAATGGCAGTGAAGATGAAATGAGATTTTCGAGAAGCTGTGATGGAACG
 100 116
 G N G S E D E M R F R E A V M E R

 473 520
 CATGAGCAACATGGAAAGCAGAATCCAGTATCTTTCAGATAATGAAGCCA
 117 133
 M S N M E S R I Q Y L S D N E A N

 523 570
 ATCTCCTAGATGCTAAGAATTTCCAAAATTTTCAGCATAACAACTGATCAA
 134 149
 L L D A K N F Q N F S I T T D Q

FIG. 4A

573
AGATTTAATGATGTTCTTTTCCAGCTAAATTCCTTACTTTCTCCATCCA 620
150
R F N D V T F Q T N S L L S S I Q 166

623
GGAACATGAGAATATCATAGGGGATATCTCCAAGTCATTAGTAGGTCTGA 670
167
E H E N I I G D I S K S L V G L N 183

673
ACACCACAGTACTTGATTGTCAGTTCAGTATTGAAACACTGAATGGCAGA 720
184
T T V L D L Q F S I E T L N G R 199

723
GTCCAAGAGAATGCATTTAAACAACAAGAGGAGATGCGTAAATTAGAGGA 770
200
V Q E N A F K Q Q E E M R K L E E 216

773
GCGTATATACAATGCATCAGCAGAAATTAAGTCTCTAGATGAAAAACAAG 820
217
R I Y N A S A E I K S L D E K Q V 233

823
TATATTTGGAACAGGAAATAAAAGGGGAAATGAAACTGTTGAATAATATC 870
234
Y L E Q E I K G E M K L L N N I 249

873
ACTAATGATCTGAGGCTGAAGGATTGGGAACATTCTCAGACATTGAAAAA 920
250
T N D L R L K D W E H S Q T L K N 266

923
TATCACTTTACTCCAAGGTCCTCCTGGACCTCCAGGTGAAAAAGGAGATA 970
267
I T L L Q G P P G P P G E K G D R 283

973
GAGGCCCTCCTGGACAAAATGGTATACCAGGCTTTCCAGGTCTAATAGGT 1020
284
G P P G Q N G I P G F P G L I G 299

FIG. 4B

1023 1070
ACTCCAGGTCTTAAAGGTGATCGGGGGATCTCTGGTTTACCTGGAGTTTCG
300 316
T P G L K G D R G I S G L P G V R

1073 1120
AGGATTCCCAGGACCAATGGGGAAGACCGGGAAGCCAGGACTTAATGGAC
317 333
G F P G P M G K T G K P G L N G Q

1123 1170
AAAAAGGCCAGAAGGGAGAAAAACCCACTCCAACCATCCAAACACAATCT
334 349
K G Q K G E K G S G S M Q R Q S

1173 1220
AATACAGTCCGACTGGTGGGTGGCAGCGGCCCTCACGAAGGCAGAGTGGA
350 366
N T V R L V G G S G P H E G R V E

1223 1270
GATTTTTTCACGAAGGCCAGTGGGGTACGGTGTGTGACGACCGCTGGGAAC
367 383
I F H E G Q W G T V C D D R W E L

1273 1320
TGCGTGGAGGACTGGTCGTCTGCAGGAGCTTGGGATACAAAGGTGTTCAA
384 399
R G G L V V C R S L G Y K G V Q

1323 1370
AGTGTGCATAAGCGAGCTTATTTTGGAAAAGGTACGGGTCCAATATGGCT
400 416
S V H K R A Y F G K G T G P I W L

1373 1420
GAATGAAGTATTTTGTTCCTCCCAAAGAGTCATCCATTGAAGAGTGCAGAA
417 433
N E V F C F G K E S S I E E C R I


1423 1470
TTAGACAGTGGGGTGTGAGAGCCTGTTCGCACGACGAAGATGCTGGGGTC
434 449
R Q W G V R A C S H D E D A G V

FIG. 4C



1473 1520
ACTTGCACTACATAATGCATCATATTTTCATTACATTTTTTAACTGTT
450
T C T T *

1523 1570
ATAAAGTGATTTTTTTCCTTTGCTTCACTAAAATCAGCTTAATTAATATT
1573 1620
TAAGAACTAAGAATTTTATCCACAGAAAAGGAATTTTAAAAATCACTG
1623 1670
GATAACATATAAAATAGCTTCATATTTGCTTCAAATACCAGAACCATT
1673
CAACTTCTGTAGGTTTTTAAGTGGCTCGTGCCGAATTC

FIG. 4D

**FIG. 5**

| | | | |
|-----------|---|---|---|
| Sialidase | - | + | - |
| Endo F | - | - | + |

*FIG. 6**FIG. 7*


A. DiI-Ac-LDL-UPTAKE

B. IgG-DI IMMUNOBLOT

① DiI-Ac-LDL Alone



② With Excess Unlabeled Ac-LDL



| | | |
|---------|---|---|
| Trypsin | - | + |
|---------|---|---|

Molecular Weight $\times 10^{-3}$

200—

116—

97—

67—


43—

A

B


FIG. 8



| 200 nM PMA | - | + |
|--|-----|------|
| Acetyl-LDL Degradation (ng/mg/5hr) | 165 | 1347 |
| Filter Binding Assay (ng/mg) | 110 | 1044 |




Ligand Blot

FIG. 9

**FIG. 10**

**FIG. 11****FIG. 12**

16/20

**FIG. 13**

-45

AGAGAAGTGGATAAATCAGTGCTGCTTTCTTTAGGACGAAAGAAGTATGGAGCA
M E Q

10

GTGGGATCACTTTCACAATCAACAGGAGGACACTGATAGCTGCTCCGAATCTGT
W D H F H N Q Q E D T D S C S E S V

64

GAAATTTGATGCTCGCTCAATGACAGCTTTGCTTCCTCCGAATCCTAAAAACAG
K F D A R S M T A L L P P N P K N S

118

CCCTTCCCTTCAAGAGAACTGAAGTCCTTCAAAGCTGCACTGATTGCCCTTTA
P S L Q E K L K S F K A A L I A L Y

172

CCTCCTCGTGTGTTGTCAGTTCTCATCCCTCTCATTGGAATAGTGGCAGCTCAACT
L L V F A V L I P L I G I V A A Q L

226

CCTGAAGTGGGAAACGAAGAATTGCTCAGTTAGTTCAACTAATGCAAATGATAT
L K W E T K N C S V S S T N A N D I

280

AACTCAAAGTCTCACGGGAAAAGGAAATGACAGCGAAGAGGAAATGAGATTTC
T Q S L T G K G N D S E E E M R F Q

334

AGAAGTCTTTATGCAACACATGAGCAACATGGAGAAGAGAATCCAGCATATTTT
E V F M E H M S N M E K R I Q H I L

388

AGACATGGAAGCCAACCTCATGGACACAGAGCATTTCAAAATTTTCAGCATGAC
D M E A N L M D T E H F Q N F S M T

FIG. 14A

442

AACTGATCAAAGATTTAATGACATTCTTCTGCAGCTAAGTACCTTGTTTTCTC
T D Q R F N D I L L Q L S T L F S S

496

AGTCCAGGGACATGGGAATGCAATAGATGAAATCTCCAAGTCCTTAATAAGTTT
V Q G H G N A I D E I S K S L I S L

550

GAATACCACATTGCTTGATTTGCAGCTCAACATAGAAAATCTGAATGGCAAAT
N T T L L D L Q L N I E N L N G K I

604

CCAAGAGAATACCTTCAAACAACAAGAGGAAATCAGTAAATTAGAGGAGCGTGT
Q E N T F K Q Q E E I S K L E E R V

658

TTACAATGTATCAGCAGAAATTATGGCTATGAAAGAAGAACAAGTGCATTGGA
Y N V S A E I M A M K E E Q V H L E

712

ACAGGAAATAAAAGGAGAAGTGAAAGTACTGAATAACATCACTAATGATCTGAG
Q E I K G E V K V L N N I T N D L R

766

ACTGAAAGATTGGGAACATTCTCAGACCTTGAGAAATATCACTTTAATTCAAGG
L K D W E H S Q T L R N I T L I Q G

820

TCCTCCTGGACCCCCGGGTGAAAAAGGAGATCGAGGTCCCACTGGAGAAAGTGG
P P G P P G E K G D R G P T G E S G

874

TCCACGAGGATTTCCAGGTCCAATAGGTCCTCCGGGTCTTAAAGGTGATCGGGG
P R G F P G P I G P P G L K G D R G

FIG. 14B

19/20

928

AGCAATTGGCTTTCCTGGAAGTCGAGGACTCCCAGGATATGCCGGAAGGCCAGG
A I G F P G S R G L P G Y A G R P G

982

AAATTCTGGACCAAAAGGCCAGAAAGGGGAAAAGGGGAGTGGAAACACATTAAC
N S G P K G Q K G E K G S G N T L T

1036

TCCATTTACGAAAGTTCGACTGGTCGGTGGGAGCGGCCCTCACGAGGGGAGAGT
P F T K V R L V G G S G P H E G R V

1090

GGAGATACTCCACAGCGGCCAGTGGGGTACAATTTGTGACGATCGCTGGGAAGT
E I L H S G Q W G T I C D D R W E V

1144

CGCGGTTGGACAGGTCGTCTGTAGGAGCTTGGGATACCCAGGTGTTCAAGCCGT
R V G Q V V C R S L G Y P G V Q A V

1198

GCACAAGGCAGCTCACTTTGGACAAGGTACTGGTCCAATATGGCTGAATGAAGT
H K A A H F G Q G T G P I W L N E V

1252

GTTTTGTTTTGGGAGAGAATCATCTATTGAAGAATGTAAAATTCGGCAATGGGG
F C F G R E S S I E E C K I R Q W G

1306

GACAAGAGCCTGTTACATTCTGAAGATGCTGGAGTCACTTGCACTTTATAATG
T R A C S H S E D A G V T C T L *

1360

CATCATATTTTCATTCACTATGAAATCGCTGCTCAAAAATGATTTTATTAC

FIG. 14C

20/20

1414

CTTGTTCCCTGTAAAATCCATTTAATCAATATTTAAGAGATTAAGAATATTGCC

1468

AAATAATATTTTAGATTACAGGATTAATATATTGAACACCTTCATGCTTACTAT

1522

TTTATGTCTATATTTAAATCATTTTAACTTCTATAGGTTTTTAAATGGAATTTT

1576

CTAATATAATGACTTATATGCTGAATTGAACATTTTGAAGTTTATAGCTTCCAG

1630

ATTACAAAGGCCAAGGGTAATAGAAATGCATACCAGTAATTGGCTCCAATTCAT

1684

AATATGTTCAACCAGGAGATTACAATTTTTTGCTCTTCTTGCTTTGTAATCTAT

1738

TTAGTTGATTTTAATTACTTTCTGAATAACGGAAGGGATCAGAAGATATCTTTT

1792

GTGCCTAGATTGCAAAATCTCCAATCCACACATATTGTTTTAAATAAGAATGT

1846

TATCCAACCTATTAAGATATCTCAATGTGCAATAACTTGTGTATTAGATATCAAT

1900

GTTAATGATATGTCTTGCCACTATGGACCAGGGAGCTTATTTTTCTTGTCATG

1954

TACTGACAACTGTTTAATTGAATCATGAAGTAAATTGCC

FIG. 14D

INTERNATIONAL SEARCH REPORT

International Application No. **PCT/US 89/05116**

I. CLASSIFICATION OF SUBJECT MATTER (if several classification symbols apply, indicate all) *

According to International Patent Classification (IPC) or to both National Classification and IPC

**IPC⁵: C 07 K 15/12, A 61 K 37/02, C 12 P 21/08, G 01 N 33/577,
G 01 N 33/92, C 12 N 15/12**

II. FIELDS SEARCHED

Minimum Documentation Searched ?

Classification System

Classification Symbols

IPC⁵

G 01 N, A 61 K

Documentation Searched other than Minimum Documentation
to the Extent that such Documents are Included in the Fields Searched *

III. DOCUMENTS CONSIDERED TO BE RELEVANT*

| Category * | Citation of Document, ** with Indication, where appropriate, of the relevant passages ** | Relevant to Claim No. ** |
|------------|--|--------------------------|
| Y | EP, A, 0189688 (NAKAGAMI) 6 August 1986 see the whole document cited in the application | 1-18 |
| P,X | Proc. Natl. Acad. Sci. USA, volume 85, December 1988, T. Kadoma et al.: "Purification and characterization of a bovine acetyl low density lipoprotein receptor", pages 9238-9242 see the whole article | 1-13 |
| Y | -- | 14-18 |
| A | The Journal of Biological Chemistry, volume 260, no. 12, 25 June 1985, The American Society of Biological Chemists, Inc., (US), D.P. Via et al.: "Murine macrophage tumors are a source of a 260,000- Dalton acetyl-low density lipoprotein receptor", pages 7379-7386 see the whole article | 1-18 |

* Special categories of cited documents: 10

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

IV. CERTIFICATION

Date of the Actual Completion of the International Search

Date of Mailing of this International Search Report

9th March 1990

12. 04. 90

International Searching Authority

Signature of Authorized Officer

EUROPEAN PATENT OFFICE

T.K. WILLIS

FURTHER INFORMATION CONTINUED FROM THE SECOND SHEET

V. ☒ OBSERVATIONS WHERE CERTAIN CLAIMS WERE FOUND UNSEARCHABLE

This International search report has not been established in respect of certain claims under Article 17(2) (a) for the following reasons:

1. ☒ Claim numbers 19-32 because they relate to subject matter not required to be searched by this Authority, namely:

Pls. see Rule 39.1 (iv) - PCT:

Methods for treatment of the human or animal body by surgery or therapy as well as diagnostic methods.

2. ☐ Claim numbers _____, because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

3. ☐ Claim numbers _____, because they are dependent claims and are not drafted in accordance with the second and third sentences of PCT Rule 6.4(a).

VI. ☐ OBSERVATIONS WHERE UNITY OF INVENTION IS LACKING

This International Searching Authority found multiple inventions in this international application as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims of the international application.
2. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims of the international application for which fees were paid, specifically claims:
3. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claim numbers:
4. ☐ As all searchable claims could be searched without effort justifying an additional fee, the International Searching Authority did not invite payment of any additional fee.

Remark on Protest

- ☐ The additional search fees were accompanied by applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

**ANNEX TO THE INTERNATIONAL SEARCH REPORT
ON INTERNATIONAL PATENT APPLICATION NO.**

US 8905116
SA 32786

This annex lists the patent family members relating to the patent documents cited in the above-mentioned international search report. The members are as contained in the European Patent Office EDP file on 03/04/90. The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

| Patent document cited in search report | Publication date | Patent family member(s) | Publication date |
|---|---------------------|----------------------------|---------------------|
| EP-A- 0189688 | 06-08-86 | JP-A- 61130238 | 18-06-86 |